Bioptix (BIOP) Getting Somewhat Positive News Coverage, Study Finds
Headlines about Bioptix (NASDAQ:BIOP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bioptix earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave news coverage about the technology company an impact score of 44.363935756927 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Bioptix (BIOP) traded down 3.63% during midday trading on Wednesday, reaching $3.72. The company’s stock had a trading volume of 7,465 shares. Bioptix has a one year low of $2.14 and a one year high of $5.92. The stock’s 50-day moving average is $3.89 and its 200-day moving average is $3.64. The company’s market capitalization is $16.41 million.
ILLEGAL ACTIVITY NOTICE: “Bioptix (BIOP) Getting Somewhat Positive News Coverage, Study Finds” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/bioptix-biop-getting-somewhat-positive-news-coverage-study-finds.html.
Bioptix, Inc, formerly Venaxis, Inc, provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered.
Receive News & Ratings for Bioptix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioptix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.